Paul Lammers

Paul Lammers, M.D., M.Sc., joined ImmunMet’s Board of Directors in November 2017. Dr. Lammers currently serves as an independent biotech consultant and Scientific Advisor to life sciences companies. In August 2017, he successfully completed a reverse merger of Mirna Therapeutics, the company he served as Director, President, and CEO since 2009, with Synlogic of Cambridge, MA. During his tenure at Mirna Therapeutics, Dr. Lammers raised approximately $160 million in funding, from Federal and State grants (including CPRIT, the Cancer Prevention and Research Institute from Texas), traditional and strategic venture firms, and by bringing the company public on the Nasdaq Capital Market. In 2009, Dr. Lammers served as President of Repros Therapeutics, The Woodlands, Texas. Prior to Repros Therapeutics, he served six years as Chief Medical Officer and Head of US Product Development for EMD Serono Inc., a subsidiary of German Pharmaceutical company, Merck KgA. Over his 20 years in the pharmaceutical and biotech industry, Dr. Lammers held different executive and senior management positions in clinical development, medical affairs, and regulatory affairs at both medium and large pharmaceutical companies, and small private and public biotech companies. He began his pharmaceutical career at Organon in the Netherlands, and is a former member of the Board of the New England Healthcare Institute (NEHI) and former Chairman of the Board of BioSymposia, an accredited provider of continuing medical education (CME) programs for medical scientists and healthcare professionals. Dr. Lammers received his Medical Degree and Masters of Science degree from the Catholic University in Nijmegen, The Netherlands.